Published in N Engl J Med on September 20, 2003
Effects of Parathyroid Hormone in Men With Osteoporosis | NCT00000427
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption | NCT01750086
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet (2013) 5.57
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone (2007) 3.41
miR-214 targets ATF4 to inhibit bone formation. Nat Med (2012) 3.01
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
Building bone to reverse osteoporosis and repair fractures. J Clin Invest (2008) 2.40
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest (2006) 1.92
Osteoporosis in men. Endocr Rev (2008) 1.80
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab (2009) 1.78
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab (2010) 1.77
Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 1.74
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res (2013) 1.68
Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell (2010) 1.60
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int (2004) 1.57
Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res (2008) 1.55
Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study. J Bone Miner Res (2015) 1.50
Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone (2007) 1.40
De novo autoimmune hepatitis associated with PTH(1-34) and PTH(1-84) administration for severe osteoporosis in a liver transplant patient. Osteoporos Int (2011) 1.39
beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J Bone Miner Res (2004) 1.39
Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int (2006) 1.33
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int (2015) 1.29
Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord (2005) 1.27
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab (2014) 1.20
Reproducibility of results in preclinical studies: a perspective from the bone field. J Bone Miner Res (2014) 1.20
Bone fragility in men--where are we? Osteoporos Int (2006) 1.19
Osteoclasts: more than 'bone eaters'. Trends Mol Med (2014) 1.17
Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int (2008) 1.15
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol (2013) 1.10
Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem (2010) 1.10
Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet (2008) 1.06
Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Curr Osteoporos Rep (2013) 1.06
Treatment of osteoporosis in men. Bone (2012) 1.06
Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice. Bone (2011) 1.06
The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int (2004) 1.05
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int (2010) 1.04
Quantitative ultrasound predicts hip and non-spine fracture in men: the MrOS study. Osteoporos Int (2007) 1.04
Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab (2010) 1.03
Osteoporosis and skeletal fractures. HSS J (2006) 1.01
Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. Osteoporos Int (2005) 1.00
Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. J Bone Miner Res (2010) 1.00
Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab (2009) 0.99
Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab (2009) 0.99
Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res (2008) 0.98
Parathyroid hormone plus alendronate--a combination that does not add up. N Engl J Med (2003) 0.98
Osteoporotic fractures in older adults. Best Pract Res Clin Rheumatol (2006) 0.95
Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. N Engl J Med (2004) 0.94
Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos Int (2007) 0.94
Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci U S A (2006) 0.94
The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int (2011) 0.93
Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab (2012) 0.92
Adherence to alendronate in male veterans. Osteoporos Int (2007) 0.92
Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol (2011) 0.91
Bone biology and anabolic therapies for bone: current status and future prospects. J Bone Metab (2014) 0.90
BMI and low bone mass in an elderly male nursing home population. Clin Interv Aging (2006) 0.90
Diagnosis and management of osteoporosis in the older senior. Clin Interv Aging (2009) 0.90
Teriparatide - Indications beyond osteoporosis. Indian J Endocrinol Metab (2012) 0.89
Management of osteoporosis among home health and long-term care patients with a prior fracture. South Med J (2009) 0.89
Teriparatide in the management of osteoporosis. Clin Interv Aging (2007) 0.89
Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One (2010) 0.89
Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). Osteoporos Int (2005) 0.89
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2006) 0.88
A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment. Bone (2014) 0.87
Osteoporosis in the aging male: treatment options. Clin Interv Aging (2007) 0.87
Inhibition of osteoclast bone resorption by disrupting vacuolar H+-ATPase a3-B2 subunit interaction. J Biol Chem (2010) 0.87
Time-dependent changes in skeletal response to teriparatide: escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women. Bone (2010) 0.87
Causes, consequences, and treatment of osteoporosis in men. Drug Des Devel Ther (2013) 0.87
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J Clin Endocrinol Metab (2006) 0.87
Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int (2007) 0.86
Biological agents in management of osteoporosis. Eur J Clin Pharmacol (2014) 0.86
Combination therapy for osteoporosis: a reappraisal. Bonekey Rep (2014) 0.86
Intermittently administered parathyroid hormone 1-34 reverses bone loss and structural impairment in orchiectomized adult rats. Osteoporos Int (2005) 0.86
Progress in osteoporosis and fracture prevention: focus on postmenopausal women. Arthritis Res Ther (2009) 0.85
Deregulation of bone forming cells in bone diseases and anabolic effects of strontium-containing agents and biomaterials. Biomed Res Int (2014) 0.85
Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. PLoS One (2011) 0.85
Patterns of treatment in Australian men following fracture. Osteoporos Int (2010) 0.85
Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporos Int (2008) 0.85
Alendronate inhibits PTH (1-34)-induced bone morphogenetic protein expression in MC3T3-E1 preosteoblastic cells. HSS J (2007) 0.85
Osteoporosis in men. Nat Rev Endocrinol (2013) 0.85
Enhanced individual trabecular repair and its mechanical implications in parathyroid hormone and alendronate treated rat tibial bone. J Biomech Eng (2014) 0.84
Treatment of primary osteoporosis in men. Clin Interv Aging (2014) 0.84
Insulin like growth factor-I: a critical mediator of the skeletal response to parathyroid hormone. Curr Mol Pharmacol (2012) 0.84
A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. J Bone Miner Metab (2014) 0.84
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos Int (2005) 0.83
Role of RANKL inhibition in osteoporosis. Arthritis Res Ther (2007) 0.83
Marker of Bone Resorption in Acute Response to Exogenous or Endogenous Parathyroid Hormone. Biomark Insights (2008) 0.83
Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag (2006) 0.83
A roadmap to the brittle bones of cystic fibrosis. J Osteoporos (2010) 0.83
Management of osteoporosis in the aging male: focus on zoledronic acid. Clin Interv Aging (2009) 0.82
Recent advances toward the clinical application of PTH (1-34) in fracture healing. HSS J (2009) 0.82
The anabolic response to parathyroid hormone is augmented in Rac2 knockout mice. Endocrinology (2008) 0.82
Profile of teriparatide in the management of postmenopausal osteoporosis. Int J Womens Health (2010) 0.82
Impact of parathyroid hormone on bone marrow-derived stem cell mobilization and migration. World J Stem Cells (2014) 0.82
Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface. Osteoporos Int (2013) 0.81
Therapy of osteoporosis in men with teriparatide. J Osteoporos (2011) 0.81
A study of male patients with forearm fracture in Northern Ireland. Clin Rheumatol (2006) 0.81
A novel therapeutic approach with Caviunin-based isoflavonoid that en routes bone marrow cells to bone formation via BMP2/Wnt-β-catenin signaling. Cell Death Dis (2014) 0.81
Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence. Ther Adv Musculoskelet Dis (2013) 0.81
Trends in college binge drinking during a period of increased prevention efforts. Findings from 4 Harvard School of Public Health College Alcohol Study surveys: 1993-2001. J Am Coll Health (2002) 12.86
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med (2013) 8.47
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet (2013) 5.57
Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med (2012) 4.72
Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol (2009) 4.54
Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res (2006) 3.66
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab (2008) 3.64
First-in-human testing of a wirelessly controlled drug delivery microchip. Sci Transl Med (2012) 3.56
In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol (2013) 3.43
Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med (2005) 3.21
Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab (2007) 3.05
Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab (2006) 2.98
High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation (2010) 2.91
Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol (2007) 2.77
The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters. Am J Obstet Gynecol (2008) 2.60
Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med (2007) 2.54
Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care (2005) 2.52
Nonculprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: a 3-vessel optical coherence tomography study. Circ Cardiovasc Imaging (2012) 2.34
Ethnic variation in bone density in premenopausal and early perimenopausal women: effects of anthropometric and lifestyle factors. J Clin Endocrinol Metab (2002) 2.34
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer (2008) 2.16
Validation of a scoring system to predict recurrence of resected solitary fibrous tumors of the pleura. Chest (2015) 2.04
Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab (2006) 2.01
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab (2004) 2.01
Persistence of heavy drinking and ensuing consequences at heavy drinking colleges. J Stud Alcohol Drugs (2009) 1.96
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol (2009) 1.95
Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis (2003) 1.89
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol (2010) 1.88
The marketing of alcohol to college students: the role of low prices and special promotions. Am J Prev Med (2003) 1.85
Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res (2006) 1.84
Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab (2004) 1.81
Visceral fat is a negative predictor of bone density measures in obese adolescent girls. J Clin Endocrinol Metab (2010) 1.80
Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab (2009) 1.78
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab (2010) 1.77
Reducing drinking and related harms in college: evaluation of the "A Matter of Degree" program. Am J Prev Med (2004) 1.71
Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr (2010) 1.70
Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors. J Clin Endocrinol Metab (2002) 1.69
Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity. J Clin Endocrinol Metab (2013) 1.69
Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab (2006) 1.67
Bone resorption and fracture across the menopausal transition: the Study of Women's Health Across the Nation. Menopause (2012) 1.66
Fracture risk and areal bone mineral density in adolescent females with anorexia nervosa. Int J Eat Disord (2014) 1.64
Secondhand effects of student alcohol use reported by neighbors of colleges: the role of alcohol outlets. Soc Sci Med (2002) 1.63
Risk factor analysis for the recurrence of resected solitary fibrous tumours of the pleura: a 33-year experience and proposal for a scoring system. Eur J Cardiothorac Surg (2012) 1.61
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol (2004) 1.61
Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol (2008) 1.60
Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA (2008) 1.58
Discontinuation of contact precautions for methicillin-resistant staphylococcus aureus: a randomized controlled trial comparing passive and active screening with culture and polymerase chain reaction. Clin Infect Dis (2013) 1.57
Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab (2007) 1.56
FGF21 and the late adaptive response to starvation in humans. J Clin Invest (2015) 1.55
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology (2008) 1.53
Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study. J Bone Miner Res (2015) 1.50
TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab (2010) 1.48
Prospective clinical trial of bladder filling and three-dimensional dosimetry in high-dose-rate vaginal cuff brachytherapy. Int J Radiat Oncol Biol Phys (2008) 1.47
Analysis of normal retinal nerve fiber layer thickness by age, sex, and race using spectral domain optical coherence tomography. J Glaucoma (2013) 1.46
Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv (2008) 1.43
Comparison of near-infrared spectroscopy and optical coherence tomography for detection of lipid. Catheter Cardiovasc Interv (2013) 1.42
Bivalirudin versus unfractionated heparin for residual thrombus burden: a frequency-domain optical coherence tomography study. Catheter Cardiovasc Interv (2014) 1.37
Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke (2007) 1.35
Disordered eating, menstrual irregularity, and bone mineral density in female runners. Med Sci Sports Exerc (2003) 1.34
The tiger genome and comparative analysis with lion and snow leopard genomes. Nat Commun (2013) 1.32
Drinking and driving among college students: the influence of alcohol-control policies. Am J Prev Med (2003) 1.29
More Canadian students drink but American students drink more: comparing college alcohol use in two countries. Addiction (2002) 1.28
Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab (2002) 1.26
Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab (2008) 1.25
Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab (2012) 1.24
Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease. Am J Gastroenterol (2006) 1.21
Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy. Transfusion (2008) 1.21
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab (2014) 1.20
Young women with cold-activated brown adipose tissue have higher bone mineral density and lower Pref-1 than women without brown adipose tissue: a study in women with anorexia nervosa, women recovered from anorexia nervosa, and normal-weight women. J Clin Endocrinol Metab (2012) 1.18
Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res (2004) 1.18
Retracted DNA barcoding Korean birds. Mol Cells (2006) 1.17
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer (2013) 1.17
Bone loss after bariatric surgery: discordant results between DXA and QCT bone density. J Bone Miner Res (2014) 1.16
Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res (2009) 1.15
Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab (2006) 1.15
Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis (2005) 1.14
The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol (2004) 1.14
Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab (2007) 1.13
New genetic variants of Anaplasma phagocytophilum and Anaplasma bovis from Korean water deer (Hydropotes inermis argyropus). Vector Borne Zoonotic Dis (2011) 1.11
Low vitamin B6 but not homocyst(e)ine is associated with increased risk of stroke and transient ischemic attack in the era of folic acid grain fortification. Stroke (2003) 1.11
Ticks collected from selected mammalian hosts surveyed in the Republic of Korea during 2008-2009. Korean J Parasitol (2011) 1.10
Genetic evidence for a high diversity and wide distribution of endemic strains of the pathogenic chytrid fungus Batrachochytrium dendrobatidis in wild Asian amphibians. Mol Ecol (2013) 1.07
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol (2009) 1.05
Effects of low-dose prednisone on bone metabolism. J Bone Miner Res (2004) 1.05
Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med (2009) 1.05
Acupuncture for chemotherapy-induced leukopenia: exploratory meta-analysis of randomized controlled trials. J Soc Integr Oncol (2007) 1.04
Computerized tomography magnified bone windows are superior to standard soft tissue windows for accurate measurement of stone size: an in vitro and clinical study. J Urol (2009) 1.04